secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001493152-22-005743
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sigyn Therapeutics completes animal study for Sigyn Therapy; safe and well-tolerated in 8 subjects
--------------------------------------------------------------------------------

- Eight porcine subjects received up to six-hour treatments; no serious adverse events reported.
- One treatment halted due to clot from procedural deviation; no serious outcome observed.
- Company plans to submit IDE to FDA to support initiation of human clinical studies.
- In vitro studies validated broad-spectrum removal of endotoxins, cytokines, and viral pathogens.
- CEO states milestone advances clinical vision for sepsis treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000149315222005743/0001493152-22-005743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000149315222005743/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-005743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer